KRAS and neoplasm: Fourth, other important prognostic and biological factors—such as molecular tumor profiles (EGFR, KRAS, ALK mutations), PD-L1 expression, or systemic inflammatory indices beyond NLR/PLR/LMR—were not incorporated into the analysis, potentially limiting mechanistic interpretation.